Calliditas Therapeutics AB (publ) Q4 2023 Earnings Report $40.00 0.00 (0.00%) (As of 12/17/2024 ET) Earnings HistoryForecast Calliditas Therapeutics AB (publ) EPS ResultsActual EPS-$0.07Consensus EPS -$0.09Beat/MissBeat by +$0.02One Year Ago EPS-$0.01Calliditas Therapeutics AB (publ) Revenue ResultsActual Revenue$42.45 millionExpected Revenue$36.24 millionBeat/MissBeat by +$6.21 millionYoY Revenue GrowthN/ACalliditas Therapeutics AB (publ) Announcement DetailsQuarterQ4 2023Date2/21/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptCALT Earnings History 50-year Wall Street legend: “Sell this tech stock NOW” (Ad)Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies. You can watch for it for free, right here. Calliditas Therapeutics AB (publ) Earnings HeadlinesCalliditas Therapeutics to Present Four Abstracts at American Society of Nephrology (ASN) Kidney Week 2024October 17, 2024 | tmcnet.comCalliditas Therapeutics (NASDAQ:CALT) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…December 18, 2024 | Crypto 101 Media (Ad)Delisting of Calliditas Therapeutics AB (publ) from Nasdaq StockholmSeptember 16, 2024 | prnewswire.comNotice of extraordinary meeting of Calliditas Therapeutics AB (publ)September 3, 2024 | prnewswire.comCalliditas Therapeutics takes certain corporate actions following announcement by Asahi KaseiSeptember 3, 2024 | prnewswire.comSee More Calliditas Therapeutics AB (publ) Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Calliditas Therapeutics AB (publ)? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Calliditas Therapeutics AB (publ) and other key companies, straight to your email. Email Address About Calliditas Therapeutics AB (publ)Calliditas Therapeutics AB (publ) (NASDAQ:CALT), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.View Calliditas Therapeutics AB (publ) ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
